Detalhe da pesquisa
1.
Simvastatin, an HMG-CoA reductase inhibitor, exhibits anti-metastatic and anti-tumorigenic effects in endometrial cancer.
Gynecol Oncol
; 134(2): 346-55, 2014 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-24880141
2.
Reversal of obesity-driven aggressiveness of endometrial cancer by metformin.
Am J Cancer Res
; 9(10): 2170-2193, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31720081
3.
Erratum: Atorvastatin exhibits anti-tumorigenic and anti-metastatic effects in ovarian cancer in vitro.
Am J Cancer Res
; 8(5): 915, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29888764
4.
Phenformin has anti-tumorigenic effects in human ovarian cancer cells and in an orthotopic mouse model of serous ovarian cancer.
Oncotarget
; 8(59): 100113-100127, 2017 Nov 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-29245964
5.
Atorvastatin exhibits anti-tumorigenic and anti-metastatic effects in ovarian cancer in vitro.
Am J Cancer Res
; 7(12): 2478-2490, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-29312801
6.
Dual inhibition of glycolysis and glutaminolysis as a therapeutic strategy in the treatment of ovarian cancer.
Oncotarget
; 8(38): 63551-63561, 2017 Sep 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-28969010
7.
Buformin exhibits anti-proliferative and anti-invasive effects in endometrial cancer cells.
Am J Transl Res
; 8(6): 2705-15, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-27398153
8.
The HMG-CoA reductase inhibitor, simvastatin, exhibits anti-metastatic and anti-tumorigenic effects in ovarian cancer.
Oncotarget
; 7(1): 946-60, 2016 Jan 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-26503475
9.
Everolimus exhibits anti-tumorigenic activity in obesity-induced ovarian cancer.
Oncotarget
; 7(15): 20338-56, 2016 Apr 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-26959121
10.
NT1014, a novel biguanide, inhibits ovarian cancer growth in vitro and in vivo.
J Hematol Oncol
; 9(1): 91, 2016 Sep 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-27655410